UFP Technologies Net Income Rises 25.8% To $20.6 Million, But Dominican Republic Transfers Lag
The medical device contract maker's CEO said program transfers and margin improvement remain behind plan despite an 11.6% sales gain.
UFP Technologies, which develops and makes single-use medical devices and sterile packaging, reported third-quarter net income of $20.6 million, up 25.8% from $16.4 million a year earlier. CEO Mitch Rock also said scheduled program transfers to the Dominican Republic and margin improvement "remain behind plan."
Sales up 11.6%, margins wider
Net sales for the quarter ended September 30, 2026 rose 11.6% to $172.4 million from $154.6 million, the company said in an 8-K filed Tuesday. Organic growth, which strips out acquired operations, was 11.1%. MedTech sales grew 12.5%.
Gross margin widened to 29.4% from 27.7%. Diluted earnings per share were $2.64 on a standard accounting basis and $2.88 on an adjusted basis, against $2.11 and $2.39 a year ago.
Adjusted operating income grew 14.5% to $30.1 million, and adjusted EBITDA rose 15.3% to $35.4 million from $30.7 million.
Costs climbed faster than sales. Selling, general and administrative expenses jumped 21.4% to $23.2 million, or 13.4% of sales versus 12.3% a year earlier.
Nine months and the balance sheet
For the first nine months, net income rose 16.2% to $59.0 million and sales increased 10.3% to $500.6 million, with organic growth of 7.9%. Adjusted EBITDA for the period was $102.8 million, up 10.7% from $92.8 million.
Long-term debt, excluding current installments, stood at $83.5 million on September 30, down from $123.0 million at the end of 2025. Cash was $20.6 million.
What Rock said about plan and pipeline
UFP, as of its 2025 annual report, makes custom products including robotic-surgery drapes, wound care items and orthopedic implant packaging. Two customers accounted for about 24.3% and 21.5% of 2025 net sales.
Rock pointed to progress scaling new Dominican Republic programs and better margins in legacy UFP operations, and said the 2025 investment in TPI has "exceeded our expectations." Then came the caveat: transfers and margin improvement are behind plan.
Looking to 2027, he said the company has added capacity at DAS Medical to support double-digit growth, sees attractive acquisition opportunities and is working to expand its credit facility.
UFP holds a conference call Wednesday at 8:30 a.m. Eastern.